VTGN logo

VTGN
VistaGen Therapeutics Inc

18,069
Mkt Cap
$178.34M
Volume
1.69M
52W High
$4.88
52W Low
$1.90
PE Ratio
-2.84
VTGN Fundamentals
Price
$4.45
Prev Close
$4.50
Open
$4.62
50D MA
$3.83
Beta
1.36
Avg. Volume
533,419.30
EPS (Annual)
-$1.67
P/B
2.64
Rev/Employee
$8,526.32
Loading...
Loading...
News
all
press releases
VistaGen Therapeutics (NASDAQ:VTGN) Releases Earnings Results, Misses Estimates By $0.03 EPS
VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5.88% and -59.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·7d ago
News Placeholder
Examining the Future: VistaGen Therapeutics's Earnings Outlook
read more...
Benzinga·8d ago
News Placeholder
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of -1,650.00% and -25.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·10d ago
News Placeholder
VistaGen Therapeutics (NASDAQ:VTGN) Share Price Passes Above Fifty Day Moving Average - Here's Why
VistaGen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Here's Why...
MarketBeat·11d ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Vistagen to Participate in Stifel Healthcare Conference 2025
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·15d ago
News Placeholder
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +50.00% and +0.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago

Latest VTGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.